Example: Heart Attack

Search clinical trials for: Bevacizumab

Total 2701 results

NCT06061809

Not yet recruiting

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Glioblastoma
NCT06060704

Recruiting

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Metastatic Colorectal Cancer
NCT06057298

Recruiting

Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (OrganoHIPEC) (OrganoHIPEC)

Peritoneal Metastases From Colorectal Cancer
NCT06047379

Not yet recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma
NCT06041490

Not yet recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Liver Transplant; Complications | Recurrent Osteosarcoma | Hepatocarcinoma | High-Risk Cancer
NCT06040099

Not yet recruiting

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Hepatocellular Carcinoma (HCC)
NCT06039202

Not yet recruiting

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
NCT06037889

Not yet recruiting

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (BRANT)

Branch Atheromatous Disease
NCT06035133

Not yet recruiting

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

Rectal Cancer
NCT06031233

Not yet recruiting

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie (MINUTE)

Oncology | Infusion Reaction
NCT06031285

Recruiting

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Hepatocellular Carcinoma
NCT06024252

Not yet recruiting

Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study (CHANCE023)

HCC
NCT06023862

Not yet recruiting

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study) (DOVE)

Uterine Cervical Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Vulvar Cancer | Clear Cell Carcinoma | Vagina Neoplasm
NCT06011109

Not yet recruiting

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

Glioma | Glioblastoma Multiforme
NCT06011772

Not yet recruiting

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Colo-rectal Cancer
NCT06010667

Not yet recruiting

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Epithelial Ovarian Cancer
NCT06008522

Not yet recruiting

Safety and Feasibility of Immuno-OCT (DETOUR)

Barrett Esophagus | Colon Carcinoma | Gastrointestinal Dysplasia
NCT06006286

Not yet recruiting

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Metastatic Hepatocellular Carcinoma
NCT06008119

Not yet recruiting

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Colorectal Cancer Metastatic
NCT06003998

Recruiting

Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab (INTERACT-II)

Colorectal Cancer | Peritoneal Metastases
NCT06001281

Not yet recruiting

Predictive Value of Soluble CD146 in Glioblastoma Patients (MUCIGLIO-01)

Glioblastoma
NCT05998941

Not yet recruiting

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
NCT05999812

Not yet recruiting

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Colorectal Cancer
NCT05992220

Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion (ALERT-HCC)

Hepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IV
NCT05985798

Recruiting

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable
NCT05984511

Not yet recruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Tumor Thrombus
NCT05983367

Recruiting

A Study to Investigate Response to Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Patients With Advanced or Metastatic Colorectal Cancer

Colorectal Cancer | Metastatic Colon Cancer
NCT05976568

Not yet recruiting

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
NCT05975463

Not yet recruiting

Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

Hepatocellular Carcinoma
NCT05969899

Recruiting

Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

Colorectal Cancer
NCT05970302

Recruiting

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Bevacizumab | Capecitabine | Metastatic Colorectal Cancer (mCRC) | Oxaliplatin | Tislelizumab | First-Line | MSS/pMMR | RAS-mutated
NCT05970666

Not yet recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation
NCT05965141

Not yet recruiting

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Ovarian Cancer
NCT05965154

Not yet recruiting

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
NCT05956821

Not yet recruiting

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Glioblastoma Multiforme | Anaplastic Astrocytoma | Oligodendroglioma | Fibrillary Astrocytomas | Diffuse Intrinsic Brainstem Glioma
NCT05945901

Recruiting

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Colorectal Cancer
NCT05939310

Not yet recruiting

Fluorescence Guided Surgery in Breast Cancer - The MARGIN-2 Study (MARGIN-2)

Breast Cancer | Breast Cancer Invasive
NCT05936606

Recruiting

Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients

Coronary Artery Disease
NCT05934799

Recruiting

Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions

Bioequivalence
NCT05930665

Not yet recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma
NCT05926271

Recruiting

POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy (POPular GUILTY)

Acute Coronary Syndrome | CYP2C19 Polymorphism
NCT05929768

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma
NCT05908916

Not yet recruiting

Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
NCT05908786

Recruiting

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular
NCT05906524

Not yet recruiting

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Other Solid Tumors | Advanced HCC
NCT05904886

Recruiting

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

Carcinoma, Hepatocellular
NCT05904457

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors
NCT05894694

Recruiting

Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

Advanced Colorectal Carcinoma
NCT05885932

Recruiting

Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis (VISTA)

Ischemic Stroke | Vertebral Artery Stenosis
NCT05886465

Recruiting

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

Hepatocellular Carcinoma

Search clinical trials for: Bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations